Will Intercept Stock Potential Be Blindsided By FDA Letter?
FDA Warning Letter Buckles Intercept Pharma Shares; Wells Fargo Downgrades
Did Improper Practices Affect Growth Trends For Intercept Pharma's Drugs?
Credit Suisse Reiterates Intercept's Lofty $200 Price Target; Ocaliva Will Be A 'Surprisingly Solid Launch'
Ocaliva Recent News
3 Reasons Goldman Sachs Still Neutral On Intercept Pharma
Intercept's Ocaliva To Experience 'Sluggish Uptake,' Investment Thesis Now 'Rapidly Shifts' To Execution In PBC
Another Wild Ride In Intercept Pharmaceuticals
Intercept Jumps 5%, Confirms FDA's Unanimous Decision To Recommend Accelerated Ocaliva Approval